Cardiorespiratory effects of immunotherapy with interleukin-2.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1989.7.1.7PMID 2783338
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

  1987cited by this paper
• Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

  1987cited by this paper
• Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.

  1987cited by this paper
• Orthoclone OKT3 treatment of acute renal allograft rejection.

  1987cited by this paper
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

  1986cited by this paper
• Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

  1986cited by this paper
• Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

  1986cited by this paper
• Clinical effects and toxicity of interleukin‐2 in patients with cancer

  1986cited by this paper
• Clinical toxicity of interferons in cancer patients: a review.

  1986cited by this paper
• Adult respiratory distress syndrome in patients with severe neutropenia.

  1986cited by this paper
• Free radicals and myocardial injury: pharmacologic implications.

  1986cited by this paper
• A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance.

  1985cited by this paper
• In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

  1985cited by this paper
• Tumor necrosis factor (TNF).

  1985cited by this paper
• In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

  1985cited by this paper
• Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man.

  1985cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

  1985cited by this paper
• Systemic administration of recombinant human interleukin-2 in mice.

  1984cited by this paper
• Systemic administration of interleukin-2 in humans.

  1984cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

  1984cited by this paper
• Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

  1984cited by this paper
• Corticosteroid‐Mediated Immunoregulation in Man

  1982cited by this paper
• Improved Left Ventricular Diastolic Filling in Patients with Coronary Artery Disease After Percutaneous Transluminal Coronary Angioplasty

  1982cited by this paper
• Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

  1981cited by this paper
• Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.

  1981cited by this paper
• Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans.

  1981cited by this paper
• Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease.

  1977cited by this paper
• A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome.

  1975cited by this paper
• Inflammation induced by histamine, serotonin, bradykinin and compound 48-80 in the rat: antagonists and mechanisms of action.

  1974cited by this paper
• THE MIGRATION OF LYMPHOCYTES ACROSS THE VASCULAR ENDOTHELIUM IN LYMPHOID TISSUE

  1972cited by this paper
• Interaction between 'sensitized lymphocytes' and antigen in vitro. I. The release of a skin reactive factor.

  1969cited by this paper
• Patterns of septic shock in man--a detailed study of 56 patients.

  1967cited by this paper

• Mechanisms and Management of Arrhythmias in Cancer Patients

  2025influential citation
• Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms

  2024cites this paper
• Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect.

  2024cites this paper
• T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer

  2023cites this paper
• The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System

  2023cites this paper
• Atrial fibrillation, cancer and anticancer drugs.

  2023cites this paper
• Causes of death among patients with cutaneous melanoma: a US population-based study

  2023cites this paper
• Numerical Simulation of Nonlinear Dynamics of Breast Cancer Models Using Continuous Block Implicit Hybrid Methods

  2023cites this paper
• Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin

  2022cites this paper
• Drug-Induced Atrial Fibrillation / Atrial Flutter

  2022cites this paper
• Cardiotoxicity of Systemic Melanoma Treatments

  2022cites this paper
• Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study

  2022cites this paper
• Oncologic Emergencies

  2021cites this paper
• Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms

  2021cites this paper
• Chemotherapy-Induced Arrhythmias

  2021cites this paper
• Chemotherapy induced arrythmia - Under recognized and undertreated.

  2021cites this paper
• Cardiotoxic mechanisms of cancer immunotherapy - A systematic review.

  2020cites this paper
• Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database.

  2020cites this paper
• Cardiovascular Toxicity and Mortality Associated With Adoptive Cell Therapy and Tumor-infiltrating Lymphocytes for Advanced Stage Melanoma.

  2020cites this paper
• Atrial Fibrillation Associated with Anticancer Drugs

  2020cites this paper
• Anticancer drug‐induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms

  2018cites this paper
• Side Effects of Medical Cancer Therapy

  2018cites this paper
• Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management

  2018cites this paper
• Chemotherapy-Associated Arrhythmias

  2017cites this paper
• Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications.

  2017cites this paper
• Cardiotoxicity of Anticancer Therapies

  2017cites this paper
• Cardiac Rhythm Disturbances

  2017cites this paper
• Cardiovascular Toxicities Associated with Cancer Immunotherapies

  2017cites this paper
• ChestRoentgenographic Abnormalities in lL-2Recipients* Incidence andCorrelation withClinical Parameters

  2017cites this paper
• Myocardial Ischemia and Cancer Therapy

  2017cites this paper
• Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation

  2016cites this paper
• Kidney Metastatic Bone Disease

  2016cites this paper
• Atrial Fibrillation and Stroke in Cancer Patients

  2016cites this paper
• Production, quality control, and bio-distribution studies of 159Gd-EDTMP as a palliative agent for bone pain

  2015cites this paper
• In Situ Regulation of Pulmonary Macrophage TNF-a mRNA Expression by lL2*

  2015cites this paper
• [Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy].

  2015cites this paper
• Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation.

  2015cites this paper
• Cancer Chemotherapy and Cardiac Arrhythmias: A Review

  2015cites this paper
• minimal or no injury to the lung microvascular barrier Chronic interleukin-2 treatment in awake sheep causes

  2015cites this paper
• Randomized clinical trial of perioperative nerve block and continuous local anaesthetic infiltration via wound catheter versus epidural analgesia in open liver resection (LIVER 2 trial)

  2015cites this paper
• Side Effects of Targeted Therapy

  2015influential citation
• Side Effects of Cytokines Approved for Therapy

  2014cites this paper
• Chemoradiotherapy-Associated Cardiovascular Toxicity: A Need of Cardio-Oncology to Improve

  2014cites this paper
• High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

  2014influential citation
• COMBINATION THERAPY WITH AEROSOL IL-2 AND NK CELLS FOR THE TREATMENT OF OSTEOSARCOMA LUNG METASTASIS

  2014cites this paper
• 59 – Cardiac Effects of Cancer Therapy

  2014cites this paper
• Arrhythmias in Cancer and Cancer Treatment: A Review

  2014cites this paper
• Plasma Angiopoietin 2 Concentrations Are Related to Impaired Lung Function and Organ Failure in a Clinical Cohort Receiving High-Dose Interleukin 2 Therapy

  2014influential citation
• Cardiac Effects of Cancer Therapy

  2013cites this paper
• Nitric Oxide and Inflammation

  2012cites this paper
• PATHOLOGICAL, MECHANISMS OF INTERLEUKIN-TWO INDUCED HYPOTENSION AND VASCULAR LEAK SYNDROME by

  2012cites this paper
• Farmer's Lung-Induced Hypersensitivity Pneumonitis Complicated by Shock

  2012cites this paper
• Drug-Induced Atrial Fibrillation

  2012cites this paper
• Drug-induced atrial fibrillation

  2012influential citation
• Endothelial Nitric Oxide Synthase Is a Key Mediator of Interleukin-2-Induced Hypotension and Vascular Leak Syndrome

  2011cites this paper
• Stationary patterns and stability in a tumor-immune interaction model with immunotherapy

  2011cites this paper
• Cardio‐Oncology/Onco‐Cardiology

  2010cites this paper
• Maporal Hantavirus ββ-Integrin Utilization and Sensitivity to Favipiravir

  2010cites this paper
• MAPORAL HANTAVIRUS: β-INTEGRIN UTILIZATION, GENETIC ANALYSIS, AND SENSITIVITY TO ANTIVIRALS

  2010cites this paper
• Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings

  2010cites this paper
• Introducing a new entity: chemotherapy-induced arrhythmia.

  2009cites this paper
• Impact o f t he N umber o f T reatment C ourses o n t he Clinical R esponse o f P atients W ho R eceive H igh-Dose Bolus I nterleukin-2

  2008cites this paper
• Inducible Nitric Oxide Synthase (iNOS) is Not Required for IL-2–induced Hypotension and Vascular Leak Syndrome in Mice

  2008cites this paper
• HEMATOLOGIC CONDITIONS IN THE ICU

  2008cites this paper
• Chapter 81 – Intensive Care of the Cancer Patient

  2008cites this paper
• Two cases of tongue cancer treated with intra- and peri-tumoral injection of recombinant interleukin-2 alone: immunohistochemistochemical considerations to clinical tumor response.

  2008cites this paper
• Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

  2007cites this paper
• Cytokines in Human Health

  2007cites this paper
• Cytokine-Induced Vascular Leak Syndrome

  2007cites this paper
• Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs

  2006cites this paper
• ReGel® Polymer-based Delivery of Interleukin-2 as a Cancer Treatment

  2006cites this paper
• Inflammatory protein profile during systemic high dose interleukin‐2 administration

  2006cites this paper
• Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferonα: Evidence of a risk/benefit advantage of subcutaneous therapy

  2005cites this paper
• Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder

  2005cites this paper
• Cardiotoxicity of cancer therapy.

  2005cites this paper
• Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review

  2005cites this paper
• Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer

  2005cites this paper
• Zhang et al Cardiotoxicity of Interleukin-2 1341 TABLE 1 . Antibodies Used in the Immunohistochemical Studies and Their Reactivity With Rat Tissue Components Staining Name of antibody Type Reactivity method Dilution

  2005cites this paper
• The pathogenesis of endomyocardial fibrosis: the role of the eosinophil

  2004cites this paper
• Rationale for immunotherapy of renal cell carcinoma

  2004cites this paper
• Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2 : an Outcome Study ( renal cancer / lung metastasis / aerosol / interleukin-2 / inhalation / local therapy )

  2004cites this paper
• Major depression in community-dwelling middle-aged and older adults: prevalence and 2- and 4-year follow-up symptoms

  2004cites this paper
• Gene-Modified Tumor-Cell Vaccines

  2004cites this paper
• The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: Clinical trials

  2004cites this paper
• Drug- Induced Pleural Diseases

  2004cites this paper
• Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.

  2004cites this paper
• Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1

  2004cites this paper
• Cytokines induce stress protein formation in cultured cardiac myocytes

  2004cites this paper
• Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.

  2003cites this paper
• Identification of a protein fragment of interleukin 2 responsible for vasopermeability.

  2003cites this paper
• Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-α and hemodynamic changes during a sepsis-like state in cancer immunotherapy

  2003cites this paper
• Pyridoxalated haemoglobin polyoxyethylene conjugate, a nitric oxide scavenger, decreases dose-limiting hypotension associated with interleukin-2 (IL-2) therapy.

  2003cites this paper
• Determination of lymphoid cell fate is dependent on the expression status of the IL‐7 receptor

  2003cites this paper
• Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.

  2003cites this paper
• A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects

  2003cites this paper
• Effects of interleukin 2 therapy on lymphocyte magnesium levels.

  2002cites this paper
• [IL-2 gene therapy in ENT carcinomas].

  2001cites this paper
• High-output cardiac failure in a patient with prostate cancer.

  2001cites this paper
• Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.

  2001cites this paper
• Bolus high dose interleukin-2 for the treatment of malignant melanoma.

  2001cites this paper